Daniel De Carvalho

Key Research Areas
Associated Researchers
Associated Organizations

Recent Research Projects

Multimodal strategy to identify novel diagnostic and therapeutic targets in lung and pancreatic cancer

2016/17-2018/19 • $1,583,455 • PI,Other
My research program focuses on lung and pancreatic cancer, the first and fourth most common cause of cancer deaths among Canadians. These two cancers account for 16% of new cancer cases in Canada in 2015, but disproportionately account for 33% of all cancer deaths. Currently, only 16% and 5% of...

Epigenetic Approaches to Enhance Cancer Immunotherapy and to Target Cancer Initiating Cells

2016/17-2018/19 • $779,294 • PI
The premise of Cancer Immunotherapy is to stimulate the patient's immune system to attack the tumour cells. Recent progress in cancer immunotherapy protocols has led to a transformation in the treatment of several types of solid tumours. However, the majority of Colorectal Cancer (CRC) patients...

Early detection of cancer in high-risk patients through profiling of circulating tumour DNA

2018/19 • $274,657 • PI,CO
Across Canada, 1 in 10 cancers occur in people with an inherited strong family risk of cancer (hereditary cancer syndrome: HCS). These families have multiple members affected with similar cancers, often at a younger age. When a family member with cancer is detected with an inherited faulty...

Cancer Epigenetics and Epigenetic Therapy

2016/17-2018/19 • $270,000 • PI
Dr. De Carvalho will lead a unique research program that develops new strategies to treat cancer. The program will determine how epigenetics, changes in gene activity caused by external factors, influences the immune system in cancer. The research results will identify innovative approaches to...

Towards the use of Epigenetic Therapy as a Primer for Cancer Immunotherapy

2016/17-2018/19 • $165,000 • PI
The main premise of Cancer Immunotherapy is to stimulate the patient's immune system to attack the malignant tumour cells. Recent progress in cancer immunotherapy protocols has led to exciting clinical results in several types of solid tumours. However, for some cancer types, such as Colorectal...

DNA-Demethylating Agents enhance cytolytic activity of CD8+ T Cells and anti-tumor immunity

2018/19 • $50,000 • Scholarship/Fellowship,Other
Recent studies have shown that DNA methyltransferase inhibitors (DNMTi) can induce IRF7 activation and Type I/III interferon signalling through dsRNA-mediated viral mimicry in cancer cells. By performing a large pan-cancer analysis using TCGA data, we determined that IRF7 activation is...

Influence of the Microbiome on Epigenetic Mechanisms in Inflammatory Bowel Disease (IBD)

2013/14-2017/18 • $1,425,000 • PI,CO
Inflammatory bowel disease (IBD) is a group of chronic intestinal inflammatory diseases that includes ulcerative colitis and Crohn's disease. Canada has one of the world's highest incidence rates with over 200,000 people suffering from some form of IBD (approximately 0.5% of the population). In...

Patents

CANCER DETECTION, CLASSIFICATION, PROGNOSTICATION, THERAPY PREDICTION AND THERAPY MONITORING USING METHYLOME ANALYSIS

There is described herein a method of detecting the presence of DNA from cancer cells in a subject comprising: providing a sample of cell-free DNA from a subject; subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; optionally denaturing the sample; capturing cell-free methylated DNA using a binder selective for methylated polynucleotides; sequencing the captured cell-free methylated DNA; comparing the sequences of the captured cell-...
Related applications: WO2018CA00203